Desmoteplase Approval For Stroke Expected In 2009, Forest Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Nine-hour treatment window could expand market. A Phase IIb/III dose-ranging study is underway. Desmoteplase is one of a handful of late-stage opportunities for Forest; the company will be in a quiet period in terms of product approvals until late in the decade.